Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) were down 3.5% during mid-day trading on Wednesday . The company traded as low as $9.40 and last traded at $10.27, with a volume of 63,735 shares changing hands. The stock had previously closed at $10.64.

Separately, Zacks Investment Research raised CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 17th.

The stock’s 50 day moving average price is $8.87 and its 200-day moving average price is $7.26. The firm’s market cap is $157.48 million.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. On average, equities research analysts forecast that CoLucid Pharmaceuticals Inc. will post ($4.01) earnings per share for the current fiscal year.

In other news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total value of $1,293,086.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.